Inovio Pharmaceuticals (NASDAQ:INO) Announces Earnings Results, Beats Estimates By $0.02 EPS

Inovio Pharmaceuticals (NASDAQ:INO) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.02, FiscalAI reports.

Here are the key takeaways from Inovio Pharmaceuticals’ conference call:

• Inovio said its INO-3107 BLA remains on track for the October 30, 2026 PDUFA date, and the FDA’s mid-cycle review raised no new significant issues. Management also said the agency reiterated plans to schedule the informal meeting on accelerated-approval eligibility.
• The company continues to believe INO-3107 supports accelerated approval based on its phase I/II data, citing large reductions in surgeries, a favorable safety profile, and a differentiated mechanism that may help patients not served by the current approved therapy.
• Inovio is building commercial readiness ahead of a potential launch, including partnerships for logistics, specialty distribution, pharmacy, and patient support. Management said it plans to commercialize with a contract sales organization and expects to benefit from learnings from the competitor’s launch.
• The company strengthened its balance sheet with a April equity offering that raised about $16 million net. Inovio ended Q1 with $37.7 million in cash and short-term investments and said its runway now extends into Q1 2027, beyond the expected PDUFA date.
• Beyond INO-3107, Inovio highlighted progress on its broader pipeline, including an Akeso/Dana-Farber collaboration in glioblastoma and advancement of its DPROT platform for rare-disease applications such as hemophilia A, Fabry disease, and hypophosphatasia.

Inovio Pharmaceuticals Trading Down 3.9%

NASDAQ:INO traded down $0.06 during trading hours on Wednesday, reaching $1.36. 3,486,565 shares of the company traded hands, compared to its average volume of 2,001,272. The business’s 50-day moving average price is $1.40 and its two-hundred day moving average price is $1.72. Inovio Pharmaceuticals has a 1 year low of $1.03 and a 1 year high of $2.98. The stock has a market capitalization of $94.09 million, a P/E ratio of -0.81 and a beta of 1.43.

Analyst Ratings Changes

Several research analysts have recently issued reports on INO shares. Wall Street Zen raised Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Oppenheimer reiterated an “outperform” rating on shares of Inovio Pharmaceuticals in a report on Friday, March 13th. Finally, Weiss Ratings cut shares of Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $6.75.

Hedge Funds Weigh In On Inovio Pharmaceuticals

A number of hedge funds have recently bought and sold shares of INO. Bridgeway Capital Management LLC bought a new stake in Inovio Pharmaceuticals during the 4th quarter valued at about $301,000. Qube Research & Technologies Ltd bought a new stake in shares of Inovio Pharmaceuticals during the second quarter valued at approximately $234,000. JPMorgan Chase & Co. raised its holdings in Inovio Pharmaceuticals by 1,667.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 65,206 shares of the biopharmaceutical company’s stock worth $153,000 after acquiring an additional 61,516 shares during the last quarter. Marshall Wace LLP bought a new position in Inovio Pharmaceuticals in the 4th quarter valued at approximately $143,000. Finally, AQR Capital Management LLC purchased a new stake in Inovio Pharmaceuticals during the 1st quarter valued at $120,000. Institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.